Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/106230
Title: Nanomedicine for glaucoma : liposomes provide sustained release of latanoprost in the eye
Authors: Natarajan, Jayaganesh V.
Ang, Marcus
Darwitan, Anastasia
Chattopadhyay, Sujay
Wong, Tina T.
Venkatraman, Subbu S.
Keywords: DRNTU::Science::Medicine
Issue Date: 2012
Source: Natarajan, J. V., Ang, M., Darwitan, A., Chattopadhyay, S., Wong, T. T., & Venkatraman, S. S. (2012). Nanomedicine for glaucoma : liposomes provide sustained release of latanoprost in the eye. International journal of nanomedicine, 2012(7), 123-131.
Series/Report no.: International journal of nanomedicine
Abstract: Purpose: To report the development and therapeutic evaluation of a liposomal nanocarrier for sustained release of latanoprost, in the rabbit eye. Methods: We fabricated latanoprost-loaded egg-phosphatidylcholine (EggPC) liposomes using the film hydration technique. The delivery vehicles were nano-sized (Z avg = 109 ± 18 nm), had a narrow poly dispersity index (PDI = 0.19 ± 0.04), and a very high loading efficiency (94% ± 5%). Based on in vitro data, we evaluated this formulation for lowering intraocular pressure (IOP) in rabbit eyes. Following a single subconjunctival injection of the latanoprost loaded formulation, the eyes were clinically monitored and the IOP recorded. Results: Latanoprost-loaded EggPC liposomes demonstrated a high drug/lipid mole ratio of 0.181, remained stable for at least 6 months on storage (4°C), and at least 1 month at 25°C. A slow and sustained release of 60% of latanoprost was achieved by 14 days in the in vitro release study. The same formulation demonstrated a greater sustained IOP lowering effect compared with daily administration of topical latanoprost beyond 90 days (4.8 ± 1.5 vs 2.5 ± 0.9 mmHg; P < 0.001). No signs of inflammation were evident in the eyes from slit-lamp examination analysis. Conclusion: The loading required for a long-term sustained delivery of latanoprost for up to 90 days in the rabbit eyes was achieved with EggPC liposomes. A single injection of latanoprost-loaded EggPC liposomes can lower the IOP for up to 90 days, with a greater IOP lowering effect than daily topical administration of latanoprost.
URI: https://hdl.handle.net/10356/106230
http://hdl.handle.net/10220/23966
URL: http://www.dovepress.com/nanomedicine-for-glaucoma-liposomes-provide-sustained-release-of-latan-peer-reviewed-article-IJN
ISSN: 1176-9114
Rights: © 2012 Natarajan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:MSE Journal Articles

Files in This Item:
File Description SizeFormat 
IJN-25468-nanomedicine-for-glaucoma--liposomes-provide-sustained-relea_010412.pdf523.83 kBAdobe PDFThumbnail
View/Open

Page view(s) 20

457
Updated on Jul 26, 2021

Download(s) 20

249
Updated on Jul 26, 2021

Google ScholarTM

Check

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.